Red PCT/PTO 10 JUN 2005

From the INTERNATIONAL SEARCHING AUTHO	RITY
To:	PCT
Davies Collison Cave Level 15 1 Nicholson Street MELBOURNE VIC 3000	NOTIFICATION OF TRANSMITTAL OF THE INTERNATIONAL SEARCH REPORT OR THE DECLARATION  (PCT Rule 44.1)
Les of olive 24.4.04°	Date of mailing 2 / EEP 200/
Applicant's or agent's file reference	(ady/month/year)
12384740	FOR FURTHER ACTION See paragraphs 1 and 4 below
International application No.	International filing date
PCT/AU2003/001665	12 December 2003
Applicant  Moπash University (et al.)	4L
The applicant is hereby notified that the international search	th report has been established and is transmitted herewith.
Filing of amendments and statement under Article 19: The applicant is entitled, if he so wishes, to amend the clai	ms of the international application (see Rule 46):
When? The time limit for filing such amendme international search report.	ents is normally two months from the date of transmittal of the
Where? Directly to the International Bure 34, chemin des Co 1211 Geneva 20, S Facsimile No.: (41	lombettes Switzerland
For more detailed instructions, see the notes on the a	ccompanying sheet.
Z. The applicant is hereby notified that no international searc to that effect is transmitted herewith.	h report will be established and that the declaration under Article 17(2)(a)
3. With regard to the protest against payment of (an) additi	onal fee(s) under Rule 40.2, the applicant is notified that:
the protest together with the decision thereon has been request to forward the texts of both the protest and the	en transmitted to the International Bureau together with the applicant's ne decision thereon to the designated Offices.
no decision has been made yet on the protest; the app	plicant will be notified as soon as a decision is made.
Reminders	
	application will be published by the International Burcau.  a notice of withdrawal of the international application, or of the priority  n Rules 90bis. 1 and 90bis. 3, respectively, before the completion of the
	some designated Offices, a demand for international preliminary pone the entry into the national phase until 30 months from the priority
	ne priority date, perform the prescribed acts for entry into the national
· · · · · · · · · · · · · · · · · · ·	hs (or later) will apply even if no demand is filed within 19 months.
See the Annex to Form PCT/IB/301 and, for details about the ap Volume II, National Chapters and the WIPO Internet site.	oplicable time limits, Office by Office, see the PCT Applicant's Guide,
Name and mailing address of the ISA/AU	Authorized officer
AUSTRALIAN PATENT OFFICE	
PO BOX 200, WODEN ACT 2606, AUSTRALIA  E-mail address: pc:@ipaustralia.gov.au	JULIE GALE
Facsimile No. (02) 6285 3929	Telephone No. (02) 6283 2272

BEST AVAILABLE COPY

# PATENT COOPERATION TREATY

# INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference 12384740	FOR FURTHER ACTION	The state of the s			
International application No.	International filing date (	(day/month/year)	(Earliest) Priority Date (day/monsh/year)		
PCT/AU2003/001665	.12 December 2003		12 December 2002		
Applicant					
Monash University (et a	il.)				
	,				
This international search report has be Article 18. A copy is being transmitt	cen prepared by this International S ed to the International Bureau.	Searching Authority and	is transmitted to the applicant according to		
This international search report consi	sts of a total of 5 sheets.	•	25		
It is also accompanied t	by a copy of each prior art documen	nt cited in this report.			
1. Basis of the report			-		
<ol> <li>With regard to the lang which it was filed, unle</li> </ol>	uage, the international search was o ss otherwise indicated under this ite	carried out on the basis o	of the international application in the language in		
the international s (Rule 23.1(b)).	earch was carried out on the basis of	of a translation of the int	ternational application furnished to this Authority		
b. With regard to any nucl carried out on the basis	leotide and/or amino acid sequenc of the sequence listing:	ce disclosed in the intern	ational application, the international search was		
X contained in the in	nternational application in written f	form.			
filed together with	n the international application in co	mputer readable form.	·		
furnished subsequ	uently to this Authority in written fo	orm.			
furnished subsequ	cently to this Authority in computer	readable form.			
the statement that application as file	the subsequently furnished written d has been furnished.	sequence listing does no	ot go beyond the disclosure in the international		
the statement that furnished	the information recorded in compu	iter readable form is iden	ntical to the written sequence listing has been		
2. Certain claims were fo	and unsearchable (See Box 1).				
3. Unity of invention is la	cking (See Box II).	٠.	*		
4. With regard to the title,	the text is approved as sul	bmitted by the applicant.			
·	the text has been establish	ned by this Authority to i	read as follows: Method		
Method of diagnosis, to of activin βc.	eatment and useful agents	for conditions cha	racterised by modulation in the level		
5. With regard to the abstract,	X the text is approved as sul	bmitted by the applicant			
	submit comments to this	n one month from the dat Authority.	8.2(b), by this Authority as it appears in Box III. te of mailing of this international search report,		
6. The figure of the drawings to	be published with the abstract is F	_			
	as suggested by the applic		X None of the figures		
	because the applicant faile				
	because this figure better	characterizes the inventi	BEST AVAILABLE COP		
			DEOI UITULE SO.		

International application No.

PCT/AU2003/001665

Box 1	Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)
This international	ional search report has not been established in respect of certain claims under Article 17(2)(a) for the following
1.	Claims Nos :
	because they relate to subject matter not required to be searched by this Authority, namely:
•	
•	
2. X	Claims Nos: 59-64
	because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically.
	Claims 59-64 relate to a pharmaceutical agent comprising an agent and to the use of an agent which is capable of modulating the functionally effective level of activin $\beta c$ subunit. The agent is not defined other than by its mode of action. The scope of the term "agent" is so broad and indeterminate that a meaningful search could not be carried out. The scope may encompass already known compounds.
3.	Claims Nos:
	because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a)
Box II	Observations where unity of invention is lacking (Continuation of item 3 of first sheet)
This Interna	tional Searching Authority found multiple inventions in this international application, as follows:
1.	As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims
2.	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.	As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos:
4.	No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
,	
Remarkon	Protest The additional search fees were accompanied by the applicant's protest.
	No protest accompanied the payment of additional search fees.

BEST AVAILABLE COPY

International application No.

PCT/AU2003/001665

CLASSIFICATION OF SUBJECT MATTER G01N 33/53; 33/574; A61K 39/395; A61P 35/00 Int. Cl. 7: According to International Patent Classification (IPC) or to both national classification and IPC FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) G01N 33/-Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) WPIDS; Medline; CA (activin beta/bc/C; inhibin; modulat\*; screen, assay, diagnos\*, immunoassay, quantif\*) DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages Relevant to Category\* claim No. WO 1998/22492 A1(THE REGENTS OF THE UNIVERSITY OF MICHIGAN) 28 May 1998. 1-58 Whole document. X Mellor, S.L. et al. (2000), Journal of Clinical Endocrinology & Metabolism, vol. 85(12), pp 4851-4858. "Localization of activin  $\beta_A$ -,  $\beta_B$ -, and  $\beta_C$ -subunits in human prostate and evidence for formation of new activin heterodimers of  $\beta_{C}$ -subunit". 1-58 X,Y Whole document. See patent family annex X Further documents are listed in the continuation of Box C Special categories of cited documents: later document published after the international filing date or priority date document defining the general state of the art and not in conflict with the application but cited to understand the principle which is not considered to be of particular or theory underlying the invention document of particular relevance; the claimed invention cannot be carlier application or patent but published on or considered novel or cannot be considered to involve an inventive step after the international filing date when the document is taken alone document of particular relevance; the claimed invention cannot be document which may throw doubts on priority "L" considered to involve an inventive step when the document is combined claim(s) or which is cited to establish the with one or more other such documents, such combination being obvious to publication date of another citation or other special a person skilled in the art reason (as specified) document member of the same patent family document referring to an oral disclosure, use, "O" exhibition or other means document published prior to the international filing date but later than the priority date claimed Date of mailing of the international search report Date of the actual completion of the international search 2 4 FEB 2004 17 February 2004 Authorized officer Name and mailing address of the ISA/AU AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA JULIE GALE E-mail address: pct@ipaustralia.gov.au Telephone No: (02) 6283 2272 Facsimile No. (02) 6285 3929

**BEST AVAILABLE COPY** 

Enom DCT/19 A MIN (cannot chant) ( luly 1998)

International application No.

PCT/AU2003/001665

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to
		claim No.
Y	EP 1 174 149 A1(KYOWA HAKKO KOGYO CO., LTD.) 23 January 2002 Whole document.	1-58
	Gold, E. J. et al., (2003 Mar 28), Molecular and Cellular Endocrinology, vol. 201, pp. 143-153. "Changes in activin and activin receptor subunit expression in rat liver during the development of CCl <sub>4</sub> -induced cirrhosis".	
P,X	Whole document.	1-58
	Mellor, S.L. et al. (2003 Oct), Endocrinology, vol. 144(10), pp. 4410-4419. "Activin βc-subunit heterodimers provide a new mechanism of regulating activin levels in the prostate".	
P,X	Whole document.	1-58
	Vejda, S. et al. (2002, Apr), Journal of Molecular Endocrinology, vol. 28, pp. 137-148. Expression and dimerization of the rat activin subunits βc and βe: evidence for the formation of novel activin dimers".	
x	Whole document.	33, 34
	Thomas, T. Z. et al., (1998), The Prostate, vol. 34, pp. 34-43. "Inhibins, activins and follistatins: expression of mRNAs and cellular localization in tissues from men with benign prostatic hyperplasia".	
x	See Table 1.	33
A	Whole document.	1-32, 34-58
<b>X, Y</b>	Risbridger, G.P. et al., (2001), Molecular and Cellular Endocrinology, vol. 180, pp. 149-153. "The contribution of inhibins and activins to malignant prostate disease". Whole document.	1-58
x	Dowling C.R. and Risbridger, G.P. (2000), Endocrine-Related Cancer, vol. 7, pp. 243-256. "The role of inhibins and activins in prostate cancer pathogenesis".  Whole document.	1-58
	Wakui, M. et al., (2001), Biochemical and Biophysical Research Communications, vol. 282, pp. 200-206. "Genes highly expressed in the early phase murine graft-versus-host reaction".	
X	Whole document.	1-3, 6, 11-13 30, 33, 37, 42 44, 46-48, 53
·	GenexBioscience, Sept 2002: 'Anti-activin beta-C: polyclonal antibody produced in rabbits immunized with a synthetic KLH-conjugated peptide'. Retrieved 5 February 2004 URL: http://www.genexbioscience.com/products.cfm?productID=146. Also, waybackmachine: http://web.archive.org/web/*/www.genexbioscience.com, retrieved	
$\mathbf{x}$	on 5 February 2002.	33-35
		ABLE CO

Information on patent family members

International application No.

PCT/AU2003/001665

1.50

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report				Pate	nt Family Member	Family Member		
WO	9822492	AU	53567/98	CA	2272545	EP	0960118	
EP	1174149	AU	38394/00	CA .	2365449	WO	0062809	
	a '					· · · · · · · · · · · · · · · · · · ·	END OF ANN	